Background: A 36-year-old white female, who had received a deceased-donor kidney transplant for end-stage renal disease secondary to reflux nephropathy 8 years previously, was referred to a transplant ...
January 26, 2009 — Detection of Haufen (cast-like, 3-dimensional polyomavirus aggregates) in the urine may provide a noninvasive means to diagnose BK polyomavirus nephropathy (BKN), according to the ...
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observed Supports progression into Phase III development ...
A phase 2 trials suggests potravitug may treat BK polyomavirus infection in kidney transplant recipients without reducing immunosuppression. Potravitug may reduce BK polyomavirus infection and ...
Please provide your email address to receive an email when new articles are posted on . FDA granted fast track designation for AntiBKV. AntiBKV is designed to treat BK polyomavirus infections in ...
BK virus (BKV) is an opportunistic pathogen that poses a significant risk to kidney transplant recipients. Often latent in healthy individuals, the virus may reactivate under intensive ...
SCHLIEREN/ZURICH, Switzerland--(BUSINESS WIRE)--Memo Therapeutics AG (“MTx”), a biotech company developing best-in-class therapeutic antibodies, announced today that the U.S. Food and Drug ...
Memo Therapeutics AG is laying plans to advance its BK polyomavirus neutralizing monoclonal antibody potravitug into phase III development after reporting positive phase II results in treating ...
Presenter: Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, U.K. About MAU868 MAU868, a first-in-class monoclonal antibody, has the potential to ...
Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to ...
BK polyomavirus (BKV) reactivation in immunocompromised renal transplant patients may result in BKV-associated nephropathy and hemorrhagic cystitis. There are no suitable animal models of BKV to date, ...
Orthogon’s small molecule therapeutics redefine treatment possibilities for BK virus infections. CANTON, Mass.–(BUSINESS WIRE)–December 10, 2024– Orthogon Therapeutics, a developer of novel antiviral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results